SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Rib-X Pharmaceuticals, Inc. Presents Data from Multiple Radezolid Studies at ICAAC Including Successful Intravenous Dosing in Phase 1 and Favorable Long-Term Safety and Tolerability Vs. Linezolid in Vivo